| Annual · values | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | -193.09% | — | — | — |
| EBITDA Margin | -188.75% | — | — | — |
| Net Margin | -257.93% | — | — | — |
| Current Ratio | 2.05 | 0.34 | 0.01 | 0.01 |
| Quick Ratio | 1.15 | 0.34 | 0.01 | 0.01 |
| Debt / Equity | — | — | — | — |
| ROE | -111.41% | 293.12% | 114.53% | 66.33% |
| ROA | -33.22% | -581.05% | -7657.14% | -4464.16% |
| Asset Turnover | 0.13 | 0.00 | — | — |
| Book Value / Share | 20.68 | -0.49 | -5.05 | -8.51 |
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for high unmet patient needs. Its primary function is to develop and launch treatments like ZELSUVMI™, a novel therapeutic product for Molluscum contagiosum infections. Notably, Pelthos Therapeutics leverages its proprietary nitric oxide-based technology platform to address significant medical challenges. The company operates in the pharmaceutical sector, specifically targeting dermatological conditions. With a strong pipeline of potential product candidates, Pelthos aims to deliver impactful treatments to patients across various demographics. Its market significance lies in addressing unmet medical needs through pioneering therapeutic innovations.